BlackRock’s TG Therapeutics TGTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.21B Sell
22,050,045
-202,885
-0.9% -$8.3M 0.02% 660
2026
Q1
$739M Buy
22,252,930
+404,468
+2% +$12.1M 0.01% 852
2025
Q4
$651M Buy
21,848,462
+548,037
+3% +$17.9M 0.01% 930
2025
Q3
$769M Sell
21,300,425
-512,881
-2% -$16.9M 0.01% 803
2025
Q2
$785M Buy
21,813,306
+318,334
+1% +$11.9M 0.01% 759
2025
Q1
$848M Sell
21,494,972
-403,786
-2% -$13.6M 0.02% 700
2024
Q4
$659M Sell
21,898,758
-57,439
-0.3% -$1.65M 0.01% 897
2024
Q3
$514M Buy
21,956,197
+10,567,851
+93% +$231M 0.01% 1052
2024
Q2
$203M Buy
11,388,346
+544,844
+5% +$8.69M ﹤0.01% 1612
2024
Q1
$165M Buy
10,843,502
+75,339
+0.7% +$1.2M ﹤0.01% 1770
2023
Q4
$184M Buy
10,768,163
+781,216
+8% +$9.08M ﹤0.01% 1699
2023
Q3
$83.5M Buy
9,986,947
+69,484
+0.7% +$969K ﹤0.01% 2096
2023
Q2
$246M Buy
9,917,463
+1,067,763
+12% +$27.6M 0.01% 1440
2023
Q1
$133M Sell
8,849,700
-284,247
-3% -$4.32M ﹤0.01% 1843
2022
Q4
$108M Buy
9,133,947
+98,897
+1% +$718K ﹤0.01% 1935
2022
Q3
$53.5M Sell
9,035,050
-227,275
-2% -$1.49M ﹤0.01% 2385
2022
Q2
$39.4M Buy
9,262,325
+326,747
+4% +$2.04M ﹤0.01% 2646
2022
Q1
$85M Buy
8,935,578
+33,413
+0.4% +$387K ﹤0.01% 2233
2021
Q4
$169M Buy
8,902,165
+42,778
+0.5% +$1.11M ﹤0.01% 1865
2021
Q3
$295M Buy
8,859,387
+507,028
+6% +$15.7M 0.01% 1423
2021
Q2
$324M Sell
8,352,359
-947,240
-10% -$37.2M 0.01% 1413
2021
Q1
$448M Buy
9,299,599
+743,313
+9% +$35.7M 0.01% 1095
2020
Q4
$445M Buy
8,556,286
+871,567
+11% +$29.4M 0.01% 987
2020
Q3
$206M Buy
7,684,719
+600,494
+8% +$13.8M 0.01% 1366
2020
Q2
$138M Buy
7,084,225
+980,779
+16% +$15.8M 0.01% 1628
2020
Q1
$60.1M Buy
6,103,446
+74,656
+1% +$943K ﹤0.01% 1949
2019
Q4
$66.9M Buy
6,028,790
+420,835
+8% +$3.2M ﹤0.01% 2188
2019
Q3
$31.5M Buy
5,607,955
+303,492
+6% +$2.12M ﹤0.01% 2554
2019
Q2
$45.9M Buy
5,304,463
+866,572
+20% +$6.55M ﹤0.01% 2366
2019
Q1
$35.7M Sell
4,437,891
-81,440
-2% -$440K ﹤0.01% 2467
2018
Q4
$18.5M Buy
4,519,331
+98,479
+2% +$489K ﹤0.01% 2756
2018
Q3
$24.8M Buy
4,420,852
+339,802
+8% +$3.88M ﹤0.01% 2747
2018
Q2
$53.7M Buy
4,081,050
+605,844
+17% +$8.33M ﹤0.01% 2319
2018
Q1
$49.3M Buy
3,475,206
+60,207
+2% +$769K ﹤0.01% 2275
2017
Q4
$28M Buy
3,414,999
+115,252
+3% +$1.01M ﹤0.01% 2613
2017
Q3
$39.1M Buy
3,299,747
+96,784
+3% +$1.1M ﹤0.01% 2433
2017
Q2
$32.2M Buy
3,202,963
+530,455
+20% +$5.94M ﹤0.01% 2508
2017
Q1
$31.1M Buy
2,672,508
+2,667,215
+50,391% +$19.1M ﹤0.01% 2491
2016
Q4
$25K Buy
5,293
+1,604
+43% +$9.41K ﹤0.01% 3193
2016
Q3
$28K Sell
3,689
-758
-17% -$4.88K ﹤0.01% 3205
2016
Q2
$27K Buy
4,447
+1,041
+31% +$8.46K ﹤0.01% 3179
2016
Q1
$29K Buy
3,406
+645
+23% +$5.64K ﹤0.01% 2657
2015
Q4
$33K Buy
2,761
+2,180
+375% +$27.5K ﹤0.01% 2298
2015
Q3
$6K Hold
581
﹤0.01% 2952
2015
Q2
$10K Sell
581
-114
-16% -$1.8K ﹤0.01% 2805
2015
Q1
$11K Buy
695
+95
+16% +$1.44K ﹤0.01% 2691
2014
Q4
$10K Hold
600
﹤0.01% 2781
2014
Q3
$6K Hold
600
﹤0.01% 3013
2014
Q2
$6K Buy
+600
New +$3.84K ﹤0.01% 3077

Other funds holding TGTX

BlackRock's TGTX Position: Q2 2026 in Review

BlackRock reduced its TG Therapeutics (TGTX) stake by 0.91% in Q2 2026, selling an estimated $8.3M and leaving 22,050,045 shares worth $1.21B. The position accounts for 0.02% of the portfolio, ranked #660.

BlackRock first reported a position in TGTX in Q2 2014 and has held it in 49 quarters since. 427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • BlackRock held 22,050,045 shares of TG Therapeutics worth $1.21B as of Q2 2026.
  • BlackRock sold 202,885 TG Therapeutics shares in Q2 2026, an estimated $8.3M.
  • TG Therapeutics made up 0.02% of BlackRock's portfolio in Q2 2026, its #660 holding.
  • BlackRock first reported a position in TG Therapeutics in Q2 2014 and has held it in 49 quarters since.
  • 427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.